5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

The large-cap pharmaceutical sector navigates significant headwinds, including potential import tariffs up to 250% under a Trump administration, patent cliffs, and regulatory pressures like Medicare price negotiations. Despite these challenges, the industry reported a better-than-expected Q2 2025, driven by continuous innovation, aggressive M&A activity, and a strategic focus on high-growth therapeutic areas such as oncology, rare diseases, and obesity. While the sector has underperformed the S&P 500 year-to-date, it trades at a lower forward P/E of 14.71x, positioning prominent drugmakers like Johnson & Johnson, Novartis, Pfizer, Bayer, and Eli Lilly as attractive long-term investments due to their robust revenue streams and profitability.

Analysis

The large-cap pharmaceutical sector is navigating a complex environment characterized by significant headwinds and resilient underlying fundamentals. Politically driven risks, including potential 250% import tariffs and a 'Most Favored Nation' pricing policy, pose a substantial threat to profitability and supply chains. These are compounded by persistent industry challenges such as patent cliffs, regulatory pressures from Medicare negotiations, and occasional pipeline setbacks. Despite these pressures, the sector demonstrated operational strength with better-than-expected second-quarter 2025 results and a positive outlook for the second half of the year. Key growth drivers remain intact, including aggressive M&A activity, where companies are acquiring innovation in high-growth areas like oncology and obesity, and a continued focus on R&D leveraging new technologies. The sector's performance, a modest 1.1% year-to-date gain, has underperformed the S&P 500's 12.0% rise, contributing to a comparatively low valuation. The industry trades at a forward 12-month P/E of 14.71X, a notable discount to both the S&P 500 (22.95X) and the broader Medical Sector (19.36X). Individual company narratives diverge: Johnson & Johnson's Innovative Medicine sales grew 2.4% in H1 despite exclusivity losses, Novartis shows strong momentum from new drugs like Pluvicto, and Pfizer is executing a $7.7 billion cost-cutting plan to drive EPS growth amid flat revenue projections. Meanwhile, Eli Lilly's GLP-1 franchise faces intensifying competition and pricing pressure, despite being a primary top-line driver.

Key Decisions for Investors

• Given the sector's forward P/E of 14.71X, a significant discount to the S&P 500, investors could consider selectively allocating to large-cap pharma for its defensive qualities, focusing on companies with durable revenue streams that can weather macroeconomic uncertainty.
• Closely monitor political developments, as proposed import tariffs and drug pricing policies represent significant downside risks to profitability and could force costly supply chain adjustments for globally integrated drugmakers.
• Differentiate investment theses among key players: favor firms with strong, diversified new product momentum like Johnson & Johnson and Novartis, while carefully assessing the execution risk in turnaround stories like Pfizer and the competitive pressures facing high-growth names like Eli Lilly.
• Continue to view M&A as a primary catalyst, as large drugmakers are actively using substantial cash reserves to acquire innovative biotechs in high-growth fields to replenish pipelines and offset future revenue erosion from patent expirations.